Knees Boost Zimmer Biomet; Turnaround Continues, But FDA Woes Linger

Zimmer Biomet reported Q4 results that reflected solid progress in the company’s turnaround efforts, with knees leading the charge. But the company is making slower-than-expected progress resolving FDA warning letter issues and faces a new bribery lawsuit in Mexico.

Milan, Italy - November 1, 2017: Zimmer Biomet Holdings logo on the website homepage. - Image
• Source: Shutterstock

Fourth-quarter 2019 revenue at Zimmer Biomet Holdings Inc. rose 2.6% over the prior year period (3.2% in constant currency) to $2.13bn, fueled by a strengthening knee business, which accounted for around 35% of the $761m total knee revenue. Growth in full-year sales was 0.6% (2.2% in constant currency), to $7.98bn and was higher than the company's expectations at the beginning of 2019, where it predicted growth between -0.5% and 0.5%. But it was still below a relatively weak 1.7% reported growth in 2018.

The company saw its knee volumes grow 7.8% in the fourth quarter, which beat Johnson & Johnson’s 1.4% quarterly...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Orthopedics

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.